Replacing antibodies: Engineering new binding proteins

Annual Review of Biomedical Engineering

Volumn 15, Issue , 2013, Pages 93-113

  Banta, Scott ^a   Dooley, Kevin ^a   Shur, Oren ^a,b  

^a Columbia University ^*  (United States)

^b BOSTON CONSULTING GROUP   (United States)

Author keywords

antibody alternatives; biosensors; bispecific proteins; molecular imaging; protein scaffolds

Indexed keywords

ANTIBODY FRAGMENT; BIOLOGICAL PROCESS; BIOMEDICAL FIELDS; EMERGING TECHNOLOGIES; MOLECULAR RECOGNITION ELEMENT; PROTEIN SCAFFOLDS; PROTEIN STABILITY; TARGETED CANCER THERAPY;

BIOMEDICAL ENGINEERING; BIOSENSORS; DRUG DELIVERY; ENGINEERING; MOLECULAR BIOLOGY; MOLECULAR IMAGING; SCAFFOLDS (BIOLOGY);

ANTIBODIES;

ALANINE AMINOTRANSFERASE; ANKYRIN; BEVACIZUMAB; BINDING PROTEIN; DISULFIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA UROGASTRONE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GREEN FLUORESCENT PROTEIN; KNOTTIN; LEUCINE; SITAGLIPTIN; STAPHYLOCOCCUS PROTEIN A; TROPONIN I; TYROSINE KINASE RECEPTOR;

ADENO ASSOCIATED VIRUS; AMINO ACID SEQUENCE; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; ANTIGEN BINDING; BACTERIUM CULTURE; BINDING AFFINITY; BIOCATALYSIS; BIOCATALYST; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER THERAPY; CELL PROLIFERATION; CELL SURFACE; CELL SURFACE DISPLAY; COLORECTAL CANCER; COMBINATORIAL LIBRARY; COMPLEMENTARITY DETERMINING REGION; CONFORMATIONAL TRANSITION; CRYSTALLOGRAPHY; DANGEROUS GOODS; DISSOCIATION CONSTANT; DISULFIDE BOND; DNA REPAIR; DNA SHUFFLING; ECBALLIUM ELATERIUM; EFFECTOR CELL; ELECTROCHEMICAL DETECTION; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; ENDOTHELIUM CELL; EPITOPE MAPPING; EUKARYOTIC CELL; EXPERIMENTAL DESIGN; EXTRACELLULAR SPACE; GENE TARGETING; GLIOBLASTOMA; GOLD STANDARD; HOMOLOGOUS RECOMBINATION; HUMAN; HYBRIDOMA; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LIMIT OF DETECTION; LYMPHATIC LEUKEMIA; MAMMAL CELL; MOLECULAR IMAGING; MOLECULAR PROBE; MOLECULAR RECOGNITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY CARCINOMA; PEPTIDE LIBRARY; PERISTALTIC PUMP; PHAGE DISPLAY; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PROKARYOTE; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN SYNTHESIS; PROTEINASE INHIBITION; QUARTZ CRYSTAL MICROBALANCE; REVIEW; SACCHAROMYCES CEREVISIAE; SECRETORY PATHWAY; SITE DIRECTED MUTAGENESIS; SOLID PHASE SYNTHESIS; SOLID TUMOR; TANDEM REPEAT; THERAPY EFFECT; TYPE I SECRETION SYSTEM; X RAY CRYSTALLOGRAPHY;

AMINO ACID MOTIFS; ANIMALS; ANTIBODIES; ANTIBODIES, BISPECIFIC; BIOTECHNOLOGY; CARRIER PROTEINS; CULTURE MEDIA; CYSTINE-KNOT MINIPROTEINS; DRUG DELIVERY SYSTEMS; GREEN FLUORESCENT PROTEINS; HUMANS; LIGANDS; NEOPLASMS; PEPTIDE LIBRARY; PEPTIDES; PROTEIN ENGINEERING; PROTEIN STRUCTURE, SECONDARY; PROTEINS;

EID: 84880545300     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-071812-152412     Document Type: Review

References (141)

1. Miller M, Shuman JD, Sebastian T, Dauter Z, Johnson PF. 2003. Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein alpha. J. Biol. Chem. 278:15178-84
2. O'Shea EK, Rutkowski R, StaffordWF, Kim PS. 1989. Preferential heterodimer formation by isolated leucine zippers from Fos and Jun. Science 245:646-48
3. Abergel RJ, CliftonMC, Pizarro JC,Warner JA, Shuh DK, et al. 2008. The siderocalin/enterobactin interaction: A link between mammalian immunity and bacterial iron transport. J. Am.Chem. Soc. 130:11524-34
4. Padlan EA, Silverton EW, Sheriff S, Cohen GH, Smith-Gill SJ, Davies DR. 1989. Structure of an antibody-Antigen complex: Crystal structure of the HyHEL-10 Fab-lysozyme complex. Proc. Natl. Acad. Sci. USA 86:5938-42
5. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, et al. 1988. Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679-82
6. Siezen RJ, De Vos WM, Leunissen JAM, Dijkstra BW. 1991. Homology modelling and protein engineering strategy of subtilases, the family of subtilisin-like serine proteinases. Protein Eng. 4:719-37
7. Ulmer KM. 1983. Protein engineering. Science 219:666-71
8. Holliger P, Hudson PJ. 2005. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23:1126-36
9. Binz HK, Amstutz P, Plückthun A. 2005. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23:1257-68
10. GebauerM, Skerra A. 2009. Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 13:245-55
11. Hey T, Fiedler E, Rudolph R, Fiedler M. 2005. Artificial, non-Antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol. 23:514-22
12. Löfblom J, Frejd FY, Ståhl S. 2011. Non-immunoglobulin based protein scaffolds. Curr. Opin. Biotechnol. 22:843-48
13. Nuttall SD,Walsh RB. 2008. Display scaffolds: Protein engineering for novel therapeutics. Curr. Opin. Pharmacol. 8:609-15
14. Skerra A. 2007. Alternative non-Antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 18:295-304
15. Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, et al. 2010. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. J. Nuclear Med. 51:892-97
16. Wurch T, Lowe P, Caussanel V, Bes C, Beck A, Corvaia N. 2008. Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: Status on discovery research and clinical validation. Curr. Pharm. Biotechnol. 9:502-9
17. Binz HK, Stumpp MT, Forrer P, Amstutz P, Plückthun A. 2003. Designing repeat proteins: Wellexpressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J. Mol. Biol. 332:489-503
18. Sarikaya M, Tamerler C, Jen AKY, Schulten K, Baneyx F. 2003. Molecular biomimetics: Nanotechnology through biology. Nat. Mater. 2:577-85
19. Dreier B, Plückthun A. 2011. Ribosome display: A technology for selecting and evolving proteins from large libraries. Methods Mol. Biol. 687:283-306
20. Dreier B, Plückthun A. 2012. Rapid selection of high-Affinity binders using ribosome display. Methods Mol. Biol. 805:261-86
21. Qi H, Lu H, Qiu HJ, Petrenko V, Liu A. 2012. Phagemid vectors for phage display: Properties, characteristics and construction. J. Mol. Biol. 417:129-43
22. Rakonjac J, Bennett NJ, Spagnuolo J, Gagic D, Russel M. 2011. Filamentous bacteriophage: Biology, phage display and nanotechnology applications. Curr. Issues Mol. Biol. 13:51-76
23. Tanaka T, Yamada R, OginoC,Kondo A. 2012. Recent developments in yeast cell surface display toward extended applications in biotechnology. Appl. Microbiol. Biotechnol. 95:577-91
24. Traxlmayr MW, Obinger C. 2012. Directed evolution of proteins for increased stability and expression using yeast display. Arch. Biochem. Biophys. 526:174-80
25. Gai SA, Wittrup KD. 2007. Yeast surface display for protein engineering and characterization. Curr. Opin. Struct. Biol. 17:467-73
26. Löfblom J. 2011. Bacterial display in combinatorial protein engineering. Biotechnol. J. 6:1115-29
27. Sidhu SS. 2000. Phage display in pharmaceutical biotechnology. Curr. Opin. Biotechnol. 11:610-16
28. Sidhu SS, Lowman HB, Cunningham BC, Wells JA. 2000. Phage display for selection of novel binding peptides. Methods Enzymol. 328:333-63
29. Sidhu SS, Weiss GA, Wells JA. 2000. High copy display of large proteins on phage for functional selections. J. Mol. Biol. 296:487-95
30. Cung K, Slater RL, Cui Y, Jones SE, Ahmad H, et al. 2012. Rapid, multiplexed microfluidic phage display. Lab Chip 12:562-65
31. Bessette PH, Rice JJ, Daugherty PS. 2004. Rapid isolation of high-Affinity protein binding peptides using bacterial display. Protein Eng. Des. Sel. 17:731-39
32. Gera N, Hussain M, Rao BM. 2012. Protein selection using yeast surface display. Methods doi:10.1016/j.ymeth.2012.03.014. In Press
33. Rakestraw J, Aird D, Aha P, Baynes B, Lipovšek D. 2011. Secretion-And-capture cell-surface display for selection of target-binding proteins. Protein Eng. Des. Sel. 24:525-30
34. Boder ET, MidelfortKS, Wittrup KD. 2000. Directed evolution of antibody fragments withmonovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. USA 97:10701-5
35. Cirino PC, Mayer KM, Umeno D. 2003. Generating mutant libraries using error-prone PCR. Methods Mol. Biol. 231:3-9
36. Stemmer WPC. 1994. Rapid evolution of a protein in vitro by DNA shuffling. Nature 370:389-91
37. HenkeE, Bornscheuer UT. 1999. Directed evolution of an esterase from Pseudomonas fluorescens.Random mutagenesis by error-prone PCR or a mutator strain and identification of mutants showing enhanced enantioselectivity by a resorufin-based fluorescence assay. Biol. Chem. 380:1029-33
38. Lai YP, Huang J, Wang LF, Li J, Wu ZR. 2004. A new approach to random mutagenesis in vitro. Biotechnol. Bioeng. 86:622-27
39. Pirakitikulr N, OstrovN, Peralta-Yahya P,Cornish VW. 2010. PCRless library mutagenesis via oligonucleotide recombination in yeast. Protein Sci. 19:2336-46
40. Esvelt KM, Carlson JC, Liu DR. 2011. A system for the continuous directed evolution of biomolecules. Nature 472:499-503
41. Majors BS, Chiang GG, Betenbaugh MJ. 2009. Protein and genome evolution in mammalian cells for biotechnology applications. Mol. Biotechnol. 42:216-23
42. Lutz S. 2010. Beyond directed evolution -semi-rational protein engineering and design. Curr. Opin. Biotechnol. 21:734-43
43. Reetz MT, Kahakeaw D, Lohmer R. 2008. Addressing the numbers problem in directed evolution. ChemBioChem 9:1797-804
44. Jäckel C, Hilvert D. 2010. Biocatalysts by evolution. Curr. Opin. Biotechnol. 21:753-59
45. Karanicolas J, Corn JE, Chen I, Joachimiak LA, Dym O, et al. 2011. A de novo protein binding pair by computational design and directed evolution. Mol. Cell 42:250-60
46. Weissleder R. 2006. Molecular imaging in cancer. Science 312:1168-71
47. Ogawa M, Kosaka N, Choyke PL, Kobayashi H. 2009. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res. 69:1268-72
48. Wu AM, Olafsen T. 2008. Antibodies for molecular imaging of cancer. Cancer J. 14:191-97
49. Boder ET, Jiang W. 2011. Engineering antibodies for cancer therapy. Annu. Rev. Chem. Biomol. Eng. 2:53-75
50. Huang L, Gainkam LOT, Caveliers V, Vanhove C, Keyaerts M, et al. 2008. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol. Imaging Biol. 10:167-75
51. Reubi JC, Maecke HR. 2008. Peptide-based probes for cancer imaging. J. Nuclear Med. 49:1735-38
52. Maecke HR, Hofmann M, Haberkorn U. 2005. 68Ga-labeled peptides in tumor imaging. J. Nuclear Med. 46:172S-78S
53. Landon LA, Deutscher SL. 2003. Combinatorial discovery of tumor targeting peptides using phage display. J. Cell. Biochem. 90:509-17
54. Britz-Cunningham SH, Adelstein SJ. 2003. Molecular targeting with radionuclides: State of the science. J. Nuclear Med. 44:1945-61
55. Orlova A, Magnusson M, Eriksson TLJ, Nilsson M, Larsson B, et al. 2006. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66:4339-48
56. Nygren PÅ . 2008. Alternative binding proteins: Affibody binding proteins developed from a small threehelix bundle scaffold. FEBS J. 275:2668-76
57. Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams G, et al. 2004. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng. Des. Sel. 17:455-62
58. Chen JS, Lan K, Hung MC. 2003. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist. Updates 6:129-36
59. Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, et al. 2007. Synthetic affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 67:2178-86
60. Moore SJ, LeungCL, Cochran Jr. 2011. Knottins: Disulfide-bonded therapeutic and diagnostic peptides. Drug Discov. Today: Technol. 9:e3-11
61. Nilsson BL, Soellner MB, Raines RT. 2005. Chemical synthesis of proteins. Annu. Rev. Biophys. Biomol. Struct. 34:91-118
62. Gracy J, Le-Nguyen D, Gelly JC,Kaas Q, Heitz A,Chiche L. 2008. KNOTTIN: The knottin or inhibitor cystine knot scaffold in 2007. Nucleic Acids Res. 36:D314-19
63. Kimura RH, Cheng Z, Gambhir SS, Cochran Jr. 2009. Engineered knottin peptides: A new class of agents for imaging integrin expression in living subjects. Cancer Res. 69:2435-42
64. AlghisiGC, Rüegg C. 2006. Vascular integrins in tumor angiogenesis: Mediators and therapeutic targets. Endothelium 13:113-35
65. Brooks PC, Clark R,Cheresh DA. 1994. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-71
66. Stupack D, Cheresh D. 2004. Integrins and angiogenesis. Curr. Top. Dev. Biol. 64:207-38
67. Miao Z, Levi J, Cheng Z. 2011. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 41:1037-47
68. Kontermann RE. 2005. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol. Sin. 26:1-9
69. Segal DM, Weiner GJ, Weiner LM. 1999. Bispecific antibodies in cancer therapy. Curr. Opin. Immunol. 11:558-62
70. Wang H, Liu Y, Wei L, Guo Y. 2002. Bi-specific antibodies in cancer therapy. Cancer Gene Therapy 465:369-80
71. Chames P, Baty D. 2009. Bispecific antibodies for cancer therapy. Curr. Opin. Drug Discov. Dev. 12:276-83
72. MullerD, Kontermann RE. 2010. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 24:89-98
73. Cochran Jr. 2010. Engineered proteins pull double duty. Sci. Transl. Med. 2:17ps5
74. Alder MN, Rogozin IB, Iyer LM, Glazko GV, Cooper MD, Pancer Z. 2005. Diversity and function of adaptive immune receptors in a jawless vertebrate. Science 310:1970-73
75. Pancer Z, Cooper MD. 2006. The evolution of adaptive immunity. Annu. Rev. Immunol. 24:497-518
76. Pancer Z, Saha NR, Kasamatsu J, Suzuki T, Amemiya CT, et al. 2005. Variable lymphocyte receptors in hagfish. Proc. Natl. Acad. Sci. USA 102:9224-29
77. Al-Khodor S, Price CT, Kalia A, Abu Kwaik Y. 2010. Functional diversity of ankyrin repeats in microbial proteins. Trends Microbiol. 18:132-39
78. D'Andrea LD, Regan L. 2003. TPR proteins: The versatile helix. Trends Biochem. Sci. 28:655-62
79. Kobe B, Kajava AV. 2001. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol. 11:725-32
80. Boersma YL, Plückthun A. 2011. DARPins and other repeat protein scaffolds: Advances in engineering and applications. Curr. Opin. Biotechnol. 22:849-57
81. Main ERG, Jackson SE, Regan L. 2003. The folding and design of repeat proteins: Reaching a consensus. Curr. Opin. Struct. Biol. 13:482-89
82. Stumpp MT, Forrer P, Binz HK, Plückthun A. 2003. Designing repeat proteins: Modular leucine-rich repeat protein libraries based on the mammalian ribonuclease inhibitor family. J. Mol. Biol. 332:471-87
83. Urvoas A, Guellouz A, Valerio-Lepiniec M, Graille M, Durand D, et al. 2010. Design, production and molecular structure of a new family of artificial alpha-helicoidal repeat proteins (αRep) based on thermostable HEAT-like repeats. J. Mol. Biol. 404:307-27
84. Kohl A, Binz HK, Forrer P, StumppMT, Pl ückthunA, GrütterMG. 2003. Designed to be stable: Crystal structure of a consensus ankyrin repeat protein. Proc. Natl. Acad. Sci. USA 100:1700-5
85. Amstutz P, BinzHK, Parizek P, StumppMT, Kohl A, et al. 2005. Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. J. Biol. Chem. 280:24715-22
86. Amstutz P, Koch H, Binz HK, Deuber SA, Plückthun A. 2006. Rapid selection of specific MAP kinasebinders from designed ankyrin repeat protein libraries. Protein Eng. Des. Sel. 19:219-29
87. Dreier B, Mikheeva G, BelousovaN, Parizek P, Boczek E, et al. 2011. Her2-specificmultivalent adapters confer designed tropism to adenovirus for gene targeting. J. Mol. Biol. 405:410-26
88. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, et al. 2007. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J. Mol. Biol. 369:1015-28
89. Boersma YL, Chao G, Steiner D, Wittrup KD, Plückthun A. 2011. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J. Biol. Chem. 286:41273-85
90. Steiner D, Forrer P, Plückthun A. 2008. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J. Mol. Biol. 382:1211-27
91. Papo N, Silverman AP, Lahti JL, Cochran Jr. 2011. Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and αvβ3 integrin. Proc. Natl. Acad. Sci. USA 108:14067-72
92. Ferrara N. 2004. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 25:581-611
93. Somanath PR, Ciocea A, Byzova TV. 2009. Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem. Biophys. 53:53-64
94. Folkman J. 2007. Angiogenesis: An organizing principle for drug discovery? Nat. Rev. Drug Discov. 6:273-86
95. Stupp R, Ruegg C. 2007. Integrin inhibitors reaching the clinic. J. Clin. Oncol. 25:1637-38
96. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, et al. 2009. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323:1610-14
97. Reid BG, Flynn GC. 1997. Chromophore formation in green fluorescent protein. Biochemistry 36:6786-91
98. Pavoor TV, Cho YK, Shusta EV. 2009. Development of GFP-based biosensors possessing the binding properties of antibodies. Proc. Natl. Acad. Sci. USA 106:11895-900
99. Abedi MR, Caponigro G, Kamb A. 1998. Green fluorescent protein as a scaffold for intracellular presentation of peptides. Nucleic Acids Res. 26:623-30
100. Doi N, Yanagawa H. 1999. Design of generic biosensors based on green fluorescent proteins with allosteric sites by directed evolution. FEBS Lett. 453:305-7
101. Dai M, Temirov J, Pesavento E, Kiss C, Velappan N, et al. 2008. Using T7 phage display to select GFP-based binders. Protein Eng. Des. Sel. 21:413-24
102. Pavan S, Berti F. 2012. Short peptides as biosensor transducers. Anal. Bioanal. Chem. 402:3055-70
103. Hong P, Li W, Li J. 2012. Applications of aptasensors in clinical diagnostics. Sensors 12:1181-93
104. Torres-Chavolla E, AlociljaEC. 2009. Aptasensors for detection ofmicrobial and viral pathogens. Biosens. Bioelectron. 24:3175-82
105. Weng CH, Huang CJ, Lee GB. 2012. Screening of aptamers on microfluidic systems for clinical applications. Sensors 12:9514-29
106. Park JP, Cropek DM, Banta S. 2010. High affinity peptides for the recognition of the heart disease biomarker troponin I identified using phage display. Biotechnol. Bioeng. 105:678-86
107. Wu J, Cropek DM, West AC, Banta S. 2010. Development of a troponin I biosensor using a peptide obtained through phage display. Anal. Chem. 82:8235-43
108. Wu J, Park JP, Dooley K, Cropek DM, West AC, Banta S. 2011. Rapid development of new protein biosensors utilizing peptides obtained via phage display. PLoS One 6:e24948
109. Huan TN, Ha VTT, Hung LQ, Yoon MY, Han SH, Chung H. 2009. Square wave voltammetric detection of Anthrax utilizing a peptide for selective recognition of a protein biomarker. Biosens. Bioelectron. 25:469-74
110. FriskML, LinG, Johnson EA, Beebe DJ. 2011. Synaptotagmin II peptide-bead conjugate for botulinum toxin enrichment and detection in microchannels. Biosens. Bioelectron. 26:1929-35
111. Goldman ER, Liu JL, Bernstein RD, Swain MD, Mitchell SQ, Anderson GP. 2009. Ricin detection using phage displayed single domain antibodies. Sensors 9:542-55
112. Ngundi MM, KulaginaNV, Anderson GP, Taitt CR. 2006. Nonantibody-based recognition: Alternative molecules for detection of pathogens. Expert Rev. Proteomics 3:511-24
113. Petrenko VA, Sorokulova IB. 2004. Detection of biological threats. A challenge for directed molecular evolution. J. Microbiol. Methods 58:147-68
114. Petrenko VA, Vodyanoy VJ. 2003. Phage display for detection of biological threat agents. J. Microbiol. Methods 53:253-62
115. Sankaran S, Panigrahi S,Mallik S. 2011. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef. Biosens. Bioelectron. 26:3103-9
116. Mannoor MS, Zhang S, Link AJ, McAlpine MC. 2010. Electrical detection of pathogenic bacteria via immobilized antimicrobial peptides. Proc. Natl. Acad. Sci. USA 107:19207-12
117. Nakamura C, Inuyama Y, Goto H, Obataya I, Kaneko N, et al. 2005. Dioxin-binding pentapeptide for use in a high-sensitivity on-bead detection assay. Anal. Chem. 77:7750-57
118. Ramoni R, Bellucci S, Grycznyski I, Grycznyski Z, Grolli S, et al. 2007. The protein scaffold of the lipocalin odorant-binding protein is suitable for the design of new biosensors for the detection of explosive components. J. Phys.: Condens. Matter 19:395012
119. Bommarius AS, Blum JK, Abrahamson MJ. 2011. Status of protein engineering for biocatalysts: How to design an industrially useful biocatalyst. Curr. Opin. Chem. Biol. 15:194-200
120. Bornscheuer U, Huisman G, Kazlauskas R, Lutz S, Moore J, Robins K. 2012. Engineering the third wave of biocatalysis. Nature 485:185-94
121. Kumar A, Singh S. 2012. Directed evolution: Tailoring biocatalysts for industrial applications. Crit. Rev. Biotechnol. doi:10.3109/07388551.2012. 716810. In Press
122. Savile CK, Janey JM, Mundorff EC,Moore JC, Tam S, et al. 2010. Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture. Science 329:305-9
123. Röthlisberger D, Khersonsky O, Wollacott AM, Jiang L, DeChancie J, et al. 2008. Kemp elimination catalysts by computational enzyme design. Nature 453:190-95
124. Davidson AL, Dassa E, Orelle C, Chen J. 2008. Structure, function, and evolution of bacterial ATPbinding cassette systems. Microbiol. Mol. Biol. Rev. 72:317-64
125. Blenner MA, Shur O, Szilvay GR, Cropek DM, Banta S. 2010. Calcium-induced folding of a beta roll motif requires C-Terminal entropic stabilization. J. Mol. Biol. 400:244-56
126. Banta S,Wheeldon IR,BlennerM. 2010. Protein engineering in the development of functional hydrogels. Annu. Rev. Biomed. Eng. 12:167-86
127. Dooley K, Kim YH, Lu HD, Tu R, Banta S. 2012. Engineering of an environmentally responsive beta roll peptide for use as a calcium-Dependent cross-linking domain for peptide hydrogel formation. Biomacromolecules 13:1758-64
128. Shur O, Wu J, Cropek DM, Banta S. 2011. Monitoring the conformational changes of an intrinsically disordered peptide using a quartz crystal microbalance. Protein Sci. 20:925-30
129. Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. 2000. Repeat transduction in the mouse lung by using adeno-Associated virus vectors with different serotypes. J. Virol. 74:1524-32
130. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, et al. 1997. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16:270-76
131. Xiao X, Li J, Samulski RJ. 1996. Efficient long-Term gene transfer intomuscle tissue of immunocompetent mice by adeno-Associated virus vector. J. Virol. 70:8098-108
132. Knipe D, Howley P. 2006. Fields Virology, Vol. 1. Philadelphia: LippincottWilliams &Wilkins
133. Bartel MA,Weinstein JR, Schaffer DV. 2012. Directed evolution of novel adeno-Associated viruses for therapeutic gene delivery. Gene Therapy 19:694-700
134. Perabo L, Büning H, Kofler DM, Ried MU, Girod A, et al. 2003. In vitro selection of viral vectors with modified tropism: The adeno-Associated virus display. Mol. Ther. 8:151-57
135. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. 2006. Directed evolution of adeno-Associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24:198-204
136. Wang J, Faust SM, Rabinowitz JE. 2011. The next step in gene delivery: Molecular engineering of adeno-Associated virus serotypes. J. Mol. Cell. Cardiol. 50:793-802
137. Koder RL, Anderson JLR, Solomon LA, Reddy KS, Moser CC, Dutton PL. 2009. Design and engineering of an O2 transport protein. Nature 458:305-9
138. Petka WA, Harden JL, McGrath KP, Wirtz D, Tirrell DA. 1998. Reversible hydrogels from selfassembling artificial proteins. Science 281:389-92
139. Ballister ER, Lai AH, Zuckermann RN, Cheng Y,Mougous JD. 2008. In vitro self-Assembly of tailorable nanotubes from a simple protein building block. Proc. Natl. Acad. Sci. USA 105:3733-38
140. Wheeldon IR, Barton SC, Banta S. 2007. Bioactive proteinaceous hydrogels from designed bifunctional building blocks. Biomacromolecules 8:2990-94
141. King NP, Sheffler W, Sawaya MR, Vollmar BS, Sumida JP, et al. 2012. Computational design of selfassembling protein nanomaterials with atomic level accuracy. Science 336:1171-74